Get 20% Off Journals at

Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer.

Sci Rep 2016 Jan 18;6:19435. Epub 2016 Jan 18.

Department of Internal Medicine (Di.M.I.), University of Genova, Genova IT.

SQLE encodes squalene epoxidase, a key enzyme in cholesterol synthesis. SQLE has sporadically been reported among copy-number driven transcripts in multi-omics cancer projects. Yet, its functional relevance has never been subjected to systematic analyses. Here, we assessed the correlation of SQLE copy number (CN) and gene expression (GE) across multiple cancer types, focusing on the clinico-pathological associations in breast cancer (BC). We then investigated whether any biological effect of SQLE inhibition could be observed in BC cell line models. Breast, ovarian, and colorectal cancers showed the highest CN driven GE among 8,783 cases from 22 cancer types, with BC presenting the strongest one. SQLE overexpression was more prevalent in aggressive BC, and was an independent prognostic factor of unfavorable outcome. Through SQLE pharmacological inhibition and silencing in a panel of BC cell lines portraying the diversity of SQLE CN and GE, we demonstrated that SQLE inhibition resulted in a copy-dosage correlated decrease in cell viability, and in a noticeable increase in replication time, only in lines with detectable SQLE transcript. Altogether, our results pinpoint SQLE as a bona fide metabolic oncogene by amplification, and as a therapeutic target in BC. These findings could have implications in other cancer types.

Download full-text PDF

Source Listing
January 2016
Get 20% Off Journals at

Similar Publications

Risk of metachronous neoplastic lesions during post-polypectomy surveillance in individuals with advanced colorectal neoplasia at initial screening colonoscopy.

J Gastroenterol Hepatol 2021 Feb 24. Epub 2021 Feb 24.

Cancer Screening Center, National Cancer Center Hospital, Tokyo, Japan.

Background And Aim: The evidence of associations between some types of advanced colorectal neoplasia (ACN) at baseline and the risk of metachronous neoplasia is inconsistent. This study aimed to elucidate the incidence of metachronous neoplasia during post-polypectomy surveillance in individuals with ACN at baseline and examine the risk factors for its high incidence.

Methods: Data from individuals who underwent endoscopic resection for ACN and received surveillance colonoscopy were analyzed. Read More

View Article and Full-Text PDF
February 2021

Sensitive quantitation of ESR1 mutations in cell-free DNA from breast cancer patients using base-specific invasive reaction assisted qPCR.

J Pharm Biomed Anal 2021 Feb 11;197:113959. Epub 2021 Feb 11.

Department of Clinical Pharmacy, Jinling Hospital, State Key Laboratory of Analytical Chemistry for Life Science & Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210002, China; The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China.

Acquired estrogen receptor 1 (ESR1) mutation is being promoted as a key mechanism of resistance to endocrine therapies in breast cancers. It is significative to monitor ESR1 mutations in real time, which provide an opportunity to alter therapy as these mutations emerge. Previous assays based on next-generation sequencing (NGS) and digital PCR (dPCR) usually due to high costs and complicated workflows hampered their clinical adoption in general medical institutions. Read More

View Article and Full-Text PDF
February 2021

Clinical trial participation assessed by age, sex, race, ethnicity, and socioeconomic status.

Contemp Clin Trials 2021 Feb 21:106315. Epub 2021 Feb 21.

Aurora NCORP, Advocate Aurora Health, 960 N 12th St., Milwaukee, WI 53233, United States of America.

Introduction: Individual demographic data and socioeconomic status (SES) factors from Census block group data may help define groups with disadvantaged access to clinical trials.

Methods: Individual demographic data from the Aurora Cancer Registry and SES factors corresponding to the Census block group of the patient's address were studied for a six-year period ending July 31, 2019.

Results: The final study cohort included 39,968 patients (enrolled = 772, and not enrolled = 39,196). Read More

View Article and Full-Text PDF
February 2021

Overcoming the barriers to optimization of adenovirus delivery using biomaterials: Current status and future perspective.

J Control Release 2021 Feb 21. Epub 2021 Feb 21.

Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Republic of Korea; Institute of Nano Science and Technology (INST), Hanyang University, Seoul 04763, Republic of Korea; GeneMedicine Co., Ltd, Seoul 04763, Republic of Korea. Electronic address:

Adenovirus (Ad) is emerging as a promising modality for cancer gene therapy due to its ability to induce high level of therapeutic transgene expression with no risk of insertional mutagenesis, ability to be facilely produced at a high titer, and capacity to induce robust antitumor immune response. Despite these excellent attributes of human serotype 5 Ad, poor systemic administration capability, coxsackie and adenovirus receptor (CAR)-dependent endocytic mechanism limiting potentially targetable cell types, nonspecific shedding to normal organs, and poor viral persistence in tumor tissues are major hindrances toward maximizing the therapeutic benefit of Ad in clinical setting. To address the abovementioned shortcomings, various non-immunogenic nanomaterials have been explored to modify Ad surface via physical or chemical interactions. Read More

View Article and Full-Text PDF
February 2021

Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq.

Cell Stem Cell 2021 Feb 18. Epub 2021 Feb 18.

Institute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, 79106 Freiburg, Germany; Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, 79106 Freiburg, Germany; Faculty of Medicine, University of Freiburg, 79110 Freiburg, Germany. Electronic address:

Genome editing has shown great promise for clinical translation but also revealed the risk of genotoxicity caused by off-target effects of programmable nucleases. Here we describe chromosomal aberrations analysis by single targeted linker-mediated PCR sequencing (CAST-Seq), a preclinical assay to identify and quantify chromosomal aberrations derived from on-target and off-target activities of CRISPR-Cas nucleases or transcriptional activator-like effector nucleases (TALENs), respectively, in human hematopoietic stem cells (HSCs). Depending on the employed designer nuclease, CAST-Seq detected translocations in 0%-0. Read More

View Article and Full-Text PDF
February 2021